Sugi Predict

Sugi Predict / Compounds / SCHEMBL1880455

SCHEMBL1880455

SCHEMBL1880455

C[C@@]1(n2ccc(N)nc2=O)O[C@H](CO)[C@@H](O)[C@@]1(N)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE3A Q14432 3/20 0.46
▸ PDE4D Q08499 1/20 0.46
▸ SLC29A1 Q99808 1/20 0.46
▸ LMNA P02545 5/20 0.46
▸ MTOR P42345 2/20 0.46
▸ THRB P10828 1/20 0.46
▸ MDM2 Q00987 1/20 0.46
▸ NCOA1 Q15788 1/20 0.46
▸ NCOA3 Q9Y6Q9 1/20 0.46
▸ CACNA1F O60840 2/20 0.37
▸ ALB P02768 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ CACNA1D Q01668 2/20 0.37
▸ CACNA1S Q13698 2/20 0.37
▸ CACNA1C Q13936 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ POLA1 P09884 1/20 0.33
▸ NT5E P21589 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL872890 0.89 PDE3A (0.47) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL5070717 0.89 PDE3A (0.47) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL18740735 0.84 PDE3A (0.45) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL28780917 0.83 PDE3A (0.45) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL1865152 0.83 PDE3A (0.46) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL27999217 0.81 PDE3A (0.52) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL4248207 0.80 PDE3A (0.40) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL3474446 0.80 PDE3A (0.53) PDE3APDE4DSLC29A1LMNAMTOR
SCHEMBL28997179 0.79 PDE3A (0.52) PDE3APDE4DSLC29A1LMNAMTOR
Hydrochloric Acid SCHEMBL3345909 0.79 PDE3A (0.52) PDE3APDE4DSLC29A1LMNAMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120171201-A1 METHODS OF TREATING HER2 POSITIVE CANCER WITH HER2 RECEPTOR ANTAGONIST IN COMBINATION WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN ENZON PHARMACEUTICALS, INC. (US) 2012-07-05 — — US disclosed
US-20120122956-A1 METHODS FOR INHIBITING ANGIOGENESIS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN ENZON PHARMACEUTICALS, INC. (US) 2012-05-17 — — US disclosed
US-20110305770-A1 RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM ENZON PHARMACEUTICALS, INC. (US) 2011-12-15 — — US disclosed
US-20110305769-A1 BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM ENZON PHARMACEUTICALS, INC. (US) 2011-12-15 — — US disclosed
US-20110230420-A1 RELEASABLE CONJUGATES FOR NUCLEIC ACIDS DELIVERY SYSTEMS ENZON PHARMACEUTICALS, INC. (US) 2011-09-22 — — US disclosed
US-20110229581-A1 RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS ENZON PHARMACEUTICALS, INC. (US) 2011-09-22 — — US disclosed
US-20110223257-A1 RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS ENZON PHARMACEUTICALS, INC. (US) 2011-09-15 — — US disclosed
US-20110111044-A1 NANOPARTICLE COMPOSITIONS FOR NUCLEIC ACIDS DELIVERY SYSTEM ENZON PHARMACEUTICALS, INC. (US) 2011-05-12 — — US disclosed
US-20110105413-A1 POLYMERIC SYSTEMS CONTAINING INTRACELLULAR RELEASABLE DISULFIDE LINKER FOR THE DELIVERY OF OLIGONUCLEOTIDES ENZON PHARMACEUTICALS, INC. (US) 2011-05-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110305769-A1 BRANCHED CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM NPC1L1, CETP, SREBF2 PDE3A 4864/4885PDE4D 4738/4885SLC29A1 865/4885
US-20110229581-A1 RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS APLNR, LPAR6, ABHD16A PDE3A 4756/4885PDE4D 4165/4885SLC29A1 132/4885
US-20110305770-A1 RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM KPNA6, LPAR6, KAT6B PDE3A 4773/4885PDE4D 4529/4885SLC29A1 166/4885
US-20120122956-A1 METHODS FOR INHIBITING ANGIOGENESIS WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN VEGFA, FLT4, FLT1 PDE3A 351/4885PDE4D 1121/4885SLC29A1 370/4885
US-20110223257-A1 RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS FUS, HNRNPUL2, HNRNPDL PDE3A 4798/4885PDE4D 4297/4885SLC29A1 409/4885
US-20110230420-A1 RELEASABLE CONJUGATES FOR NUCLEIC ACIDS DELIVERY SYSTEMS PHAX, KPNA6, KPNA2 PDE3A 4744/4885PDE4D 3861/4885SLC29A1 84/4885
US-20120171201-A1 METHODS OF TREATING HER2 POSITIVE CANCER WITH HER2 RECEPTOR ANTAGONIST IN COMBINATION WITH MULTI-ARM POLYMERIC CONJUGATES OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN ERBB2, ERBB3, EGFR PDE3A 4145/4885PDE4D 3601/4885SLC29A1 897/4885
US-20110111044-A1 NANOPARTICLE COMPOSITIONS FOR NUCLEIC ACIDS DELIVERY SYSTEM FUS, NUP205, SNX9 PDE3A 4796/4885PDE4D 4555/4885SLC29A1 342/4885
US-20110105413-A1 POLYMERIC SYSTEMS CONTAINING INTRACELLULAR RELEASABLE DISULFIDE LINKER FOR THE DELIVERY OF OLIGONUCLEOTIDES CARS1, DNAJC10, RNASE1 PDE3A 3964/4885PDE4D 3774/4885SLC29A1 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.